Drugs / Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07361094 | Nov 2025 → Jun 2028 expected | Sjogren syndrome, autoimmune hemolytic anemia, idiopathic inflammatory myopathy, systemic lupus erythematosus +1 | Beijing Boren Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07361094 ↗ |
| Action | Deplete | “enabling recognition and elimination of B-lineage cells and antibody-producing plasma cells implicated in autoimmune disease pathogenesis” NCT07361094 ↗ |
| Modality | Cell therapy | “autologous CD19-BCMA dual-target CAR T-cell therapy is a personalized cell-based immunotherapy” NCT07361094 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT07361094 ↗ |